In a collaboration with Pfizer, Draper is building three unique MPS models for liver, vascular and gastrointestinal organs. Draper’s MPS technology, more commonly described as “organs-on-a-chip technology,” aims to recapitulate human tissues, allowing researchers to measure tissue function more accurately and more quickly than in traditional preclinical models … more​

Speaking at the annual World Economic Forum in Davos, Switzerland, Pfizer CEO Ian Read said pharma has hardly earned its bad reputation, blaming instead a handful of bad actors, widespread misunderstanding, and what he sees as a woefully flawed healthcare system. … more

Intensity Therapeutics’ Series A round includes Dr. Declan Doogan, the former SVP and head of worldwide drug development at Pfizer. Intensity is focused on developing novel formulations of existing chemotherapy drugs to treat solid tumors that are bound to a cell permeation enhancer … more